Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,584.00    -31.00 (-1.92%)
Bid:
1,592.00
Ask:
1,594.00
Spread: 2.00 (0.126%)
Market Cap: £3.33b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Jun 20189:00 amRNSHikma appoints Chief Transformation Officer
1st Jun 201811:34 amRNSTotal Voting Rights
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding
17th May 20181:10 pmRNSDirector/PDMR Shareholding
15th May 20182:26 pmRNSDirector/PDMR Shareholding
3rd May 20189:00 amRNSHikma launches Methotrexate Injection
1st May 20181:38 pmRNSTotal Voting Rights
26th Apr 20181:40 pmRNSHolding(s) in Company
25th Apr 201810:41 amRNSBlock listing Interim Review
24th Apr 20189:00 amRNSHikma expands licensing agreement with Rovi
20th Apr 20189:00 amRNSHikma launches Dexrazoxane for Injection
19th Apr 201812:00 pmRNSAnnual Financial Report and Notice of AGM
10th Apr 20182:34 pmRNSDirector/PDMR Shareholding
3rd Apr 201811:19 amRNSTotal Voting Rights
29th Mar 20189:00 amRNSHikma launch-Palonosetron Hydrochloride Injection
20th Mar 20189:00 amRNSHikma has launched Ritonavir Tablets USP
19th Mar 20183:50 pmRNSDirector/PDMR Shareholding
14th Mar 20187:00 amRNSFinal Results
12th Mar 20187:00 amRNSUpdate status on ANDA for generic Advair Diskus®
9th Mar 20189:21 amRNSBlock Listing Application
27th Feb 201812:23 pmRNSNotice of Results
20th Feb 20187:00 amRNSSigurdur Olafsson appointed CEO of Hikma
13th Feb 20184:43 pmRNSHolding(s) in Company
8th Feb 201812:41 pmRNSDirector/PDMR Shareholding
8th Feb 201812:39 pmRNSDirector/PDMR Shareholding
8th Feb 201812:37 pmRNSDirector/PDMR Shareholding
26th Jan 20184:56 pmRNSHolding(s) in Company
17th Jan 20185:22 pmRNSHolding(s) in Company
15th Jan 20188:00 amRNSHikma Appoints Dr. Surendera Tyagi
4th Jan 201811:19 amRNSTotal Voting Rights
19th Dec 20179:00 amRNSHikma reaches licensing agreement with Celltrion
13th Dec 20179:00 amRNSHikma- Dihydroergotamine Mesylate Injection, USP
12th Dec 20179:59 amRNSHolding(s) in Company
11th Dec 20179:33 amRNSHolding(s) in Company
1st Dec 20179:28 amRNSTotal Voting Rights
30th Nov 20175:47 pmRNSHikma Ventures- $20.5m Series C round for Prognos
28th Nov 201710:24 amRNSAnnouncement
27th Nov 20171:38 pmRNSHikma Ventures invests in Biolinq
22nd Nov 20179:32 amRNSHolding(s) in Company
20th Nov 20179:32 amRNSHolding(s) in Company
14th Nov 20178:47 amRNSHolding(s) in Company
14th Nov 20177:00 amRNSHikma Acquires Products from Boehringer Ingelheim
8th Nov 20174:45 pmRNSHolding(s) in Company
2nd Nov 20172:51 pmRNSHolding(s) in Company
1st Nov 201711:43 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.